SEARCH

SEARCH BY CITATION

References

  • 1
    Xu J, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: final data for 2007. Natl Vital Stat Rep 2010; 58: 19.
  • 2
    Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer tresnds and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 116: 544-573.
  • 3
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemilogy and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
  • 4
    Younossi ZM, Stepanova M. Hepatitis C virus infection, age, and hispanic ethnicity increase mortality from liver cancer in the United States. Clin Gastroenterol Hepatol 2010; 8: 718-723.
  • 5
    Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life assessment in chronic liver disease: impact of type and severity of disease. Am J Gastroenterol 2001; 96: 2199-2205.
  • 6
    Afendy A, Kallman J, Stepanova M, Younoszai Z, Aquino R, Gianchi G, et al. Predictors of Health-related Quality of Life (HRQL) in patients with chronic liver disease. Aliment Pharmacol Ther 2009; 30: 469-476.
  • 7
    Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
  • 8
    Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-612.
  • 9
    Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with liver disease: a population-based study. Gut 2010; 59: 1410-1415.
  • 10
    Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.e1.
  • 11
    Stepanova M, Aquino R, Alsheddi A, Gupta R, Fang Y, Younossi Z. Clinical predictors of fibrosis in patients with chronic liver disease. Aliment Pharmacol Ther 2010; 31: 1085-1094.
  • 12
    Kumar M, Herrera J. Importance of hepatitis vaccination in patients with chronic liver disease. Southern Med J 2010; 2: 1223-1229.
  • 13
    Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995; 90: 201-205.
  • 14
    Yao G. Clinical spectrum and natural history of viral hepatitis A in a 1988 Shanghai epidemic. In: Hollinger FB, Lemon SM, Margolis HS (eds): Viral Hepatitis and Liver Disease. Baltimore, MD: Williams and Williams; 1991: 76-78.
  • 15
    Fukumoto Y, Okita K, Konishi T, Takemoto T. Hepatitis A infection in chronic carriers of hepatitis B virus. In Sung J-L, Chen D-S (eds): Viral Hepatitis and Hepatocellular Carcinoma. Amsterdam: Excerpta Medica; 1990: 43-48.
  • 16
    Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286-290.
  • 17
    Feray C, Gigou M, Samuel D, Reyes G, Bernuau J, Reynes M, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993; 104: 549-555.
  • 18
    Polish L, Shapiro C, Bauer F, Klotz P, Ginier P, Roberto R, et al. Nosocomial transmission of hepatitis B virus associated with the use of a spring-loaded finger stick device. N Engl J Med 1992: 326: 721-725.
  • 19
    Younossi ZM, Gramlich T, Matteoni C, Boparai N, McCullough A. Non-alcoholic fatty liver disease in patients with type II diabetes. Clin Gastroenterol Hepatol 2004; 2: 262-265.
  • 20
    Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238.
  • 21
    Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998; 27: 881-886.
  • 22
    Beran J, Dedek P, Stepanova V, Spliio M, Pozler O. Safety and immunogenicity of a combined vaccine against hepatitis A and B in patients with autoimmune hepatitis. Cent Eur J Public Health 2005; 13: 20-23.
  • 23
    Hadler SC, Margolis HS, Hepatitis B. Immunization: vaccine types, efficacy, and indications for immunization. In: Remington JS, Swartz MN (eds): Current Clinical Topics in Infectious Diseases. Boston, MA: Blackwell Scientific; 1992: 282-308.
  • 24
    Coates RA, Halliday ML, Rankin JG, Stewart JD, Bristow NJ, Granero R, et al. Immunogenicity and safety of a yeast-derived recombinant DNA hepatitis B vaccine in health care workers. In: Zuckerman A (ed): Viral Hepatitis and Liver Disease. New York: AR Liss; 1988: 1038-1042.
  • 25
    Dumot J, Barnes D, Younossi Z, Henderson J, Carey W. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J of Gastroenterol 1999; 94: 1601-1604.
    Direct Link:
  • 26
    Wiedmann M, Liebert UG, Oesen U, Porst H, Wiese M, Schroeder S, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000; 31: 230-234.
  • 27
    Lee SD, Chan SY, Yu MI, Wang YJ, Chang FY, Lo KJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. J Med Virol 1997; 52: 215-218.
  • 28
    Lee SD, Chan YC, Yu MI, Lu RH, Chang FY, Lo KJ. Hepatitis B vaccination in patients with chronic hepatitis C. J Med Virol 1999; 59: 463-468.
  • 29
    Recommended adult immunization schedule—United States, 2010. Morb Mortal Wkly Rep 2010; 59: 1-4.
  • 30
    Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48: 1-37.
  • 31
    Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. HEPATOLOGY 2009; 50: 661-662.
  • 32
    Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 1147-1171.
  • 33
    NIH consensus statement on management of hepatitis C: 2002. NIH Consens Statements 2002; 19: 1-46.
  • 34
    Jacobs RJ, Meyerhoff AS, Saab S. Immunization needs of chronic liver disease patients seen in primary care versus specialist settings. Digest Dis Sci 2005; 50: 1525-1531.
  • 35
    Arguedas M, Fallon M. Prevention in liver disease. Am J Med Sci 2001; 321: 145-151.
  • 36
    Shim M, Khaykis I, Park J, Bini EJ. Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. HEPATOLOGY 2005; 42: 688-695.
  • 37
    Analytic and reporting guidelines: the National Health and Nutrition Examination Survey (NHANES). Hyattsville, MD: CDC/NCHS; 2005.
  • 38
    NHANES 2005-2006 Health Insurance Questionnaire. Available at: http://www.cdc.gov/nchs/data/nhanes/nhanes_05_06/hiq_d.pdf. Accessed February 1, 2011.
  • 39
    Medicare's Physician Quality Reporting Initiative. Available at: http://www.cms.gov/PQRI/Downloads/2010_PQRI_MeasuresList_111309.pdf. Accessed February 1, 2011.
  • 40
    Kramer JR, Hachem CY, Kanwal F, Mei M, El-Serag HB. Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. HEPATOLOGY 2011; 53: 42-52.
  • 41
    Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011; 154: 319-328.
  • 42
    Zauli D, Crespi C, Fusconi M, Bonazzî L, Bianco Bianchi F, Pisi E. Different course of acute hepatitis B in elderly adults. J Gerontol 1985; 40: 415-418.
  • 43
    Hall AJ. Boosters for hepatitis B vaccination? Need for an evidence-based policy. HEPATOLOGY 2010; 51: 1485-1486.
  • 44
    Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 2007; 5: 79-84.
  • 45
    Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006; 24: 572-577.
  • 46
    Michielsen P, Vandewoude M. Liver diseases in the older adult. Acta Gastroenterologica Belgica 2010; 73: 1-4.